Introduction
The field of protein-based therapeutics is established as the fastest growing class of compounds within the pharmaceutical industry (Walsh 2003) . Since the introduction of the first recombinant therapeutic protein, human insulin in 1982, more than 120 other molecules have been approved (Dingermann 2008) . Traditionally, Escherichia coli and mammalian cell expression systems have been utilized to produce aglycosylated and glycosylated proteins, respectively. Of these systems, the use of mammalian cells, notably Chinese hamster ovary cells, has predominated due to the majority of therapeutic proteins being glycosylated. Although several forms of glycosylation exist, N-linked glycosylation is of particular interest. Protein folding, in vivo half-life and protein function have all been demonstrated to be associated with N-glycosylation (Helenius and Aebi 2001; Mitra et al. 2006) . Evolutionary conservation of this glycosylation pathway within mammalian cells has resulted in very similar glycan structures. However, differences do occur and have been the source of some concern. This is exemplified by the production of the non-human sialic acid (Sia) N-glycolylneuraminic acid in animals (Varki 2001) . As a consequence, glycoproteins produced in mammalian cell culture have been found to elicit an immune response, as evidenced by the presence of Hanganutiziu-Deicher antibodies (Higashi et al. 1977; Hokke et al. 1990 ). Other shortcomings with mammalian cell culture, including production cost, requirement for complex media and viral contamination have encouraged researchers to look for alternative systems. Many expression platforms, including insect, yeast and plant, are being developed (reviewed in Betenbaugh et al. 2004) .
The ability of yeast and filamentous fungi to grow in defined media in the absence of animal-derived growth factors, the ease of scale-up and the high yields of secreted protein have made them an attractive platform for therapeutic protein development (Punt et al. 2002) . Although the initial stages of yeast and human N-linked glycosylation pathways in the endoplasmic reticulum are similar, subsequent modifications in the Golgi differ significantly. In humans, the high-mannose (Man) structure Man 8 -N-acetylglucosamine 2 (Man 8 GlcNAc 2 ) glycan entering the Golgi is hydrolyzed by α-1,2-mannosidase to Man 5 GlcNAc 2 . Subsequently, GlcNAc is added to produce the GlcNAc-Man 5 GlcNAc 2 hybrid intermediate, which is further trimmed and extended to produce complex glycans containing a variety of terminal saccharides, including galactose (Gal) and Sia. In contrast, the Man 8 GlcNAc 2 glycan entering the yeast Golgi is further extended. Generally, only Man or Man and Gal residues are added but some species can add more unusual monosaccharides, such as xylose (Schutzbach and Ankel 1969; Fukazawa et al. 1995) . In Saccharomyces cerevisiae, following the initial addition of an α-1,6-Man by the α-1,6-mannosyl transferase (Och1p), extension of this 1,6 branch results in a hypermannosylated glycan with over 200 Man residues (Dean 1999) . The extent and linkage of residues present in hyperglycosylated glycans varies greatly, depending on the yeast strain. In the hypermannosylated glycans of S. cerevisiae Man residues can possess α-1,2, α-1,3 and α-1,6 linkages. In contrast, the pathogenic yeast Candida albicans can possess β-1,2-linked Man residues (Shibata et al. 1985) . Oral administration of β-1,2-linked oligomannosides (β-Mans) to newborn mice inhibits C. albicans colonization of the intestinal tract, strongly suggesting a role for these saccharide linkages in virulence (Dromer et al. 2002) . Deletion of OCH1 in C. albicans demonstrated that elimination of the outer chain attenuated virulence in a murine model of systemic infection Netea et al. 2006) . Furthermore, such β-structures have been established to be potent antigens for the adaptive immune response and to elicit specific infection protective antibodies (Han et al. 1997) .
The methylotrophic yeast Pichia pastoris is an important industrial organism owing to its ability to produce large amounts of protein under the control of the tightly regulated alcohol-oxidase promoter (Tschopp et al. 1987) . For example, this yeast has been reported to produce 14.8 g/L of recombinant rat gelatin (Werten et al. 1999) . Recently, extensive research has been focused on glycoengineering P. pastoris to produce human-like glycans (Hamilton and Gerngross 2007) . Choi et al. (2003) demonstrated that by knocking-out Och1p while introducing α-1,2-mannosidase (MnsI), β-1,2-N-acetylglucosaminyl transferase (GnTI) and UDP-GlcNAc transporter, hybrid glycans could be produced on a secreted recombinant kringle 3 domain. Our group subsequently engineered P. pastoris to produce complex GlcNAc-terminated human-like glycans by the introduction of MnsII and GnTII . Continuing on, our group went on to further manipulate P. pastoris to produce humanized bi-antennary glycans terminating in Sia (Hamilton et al. 2006) . Recently, P. pastoris has been reported to possess a novel family of four genes which are involved in the generation of β-Mans (Mille et al. 2008) . In this report, the P. pastoris gene and protein names were prefixed with "Pp" to distinguish them from the C. albicans ("Ca") homologs. Since the current report focuses only on the P. pastoris homologs, the species defining prefix will not be used. Independent deletion of the individual β-mannosyl transferases (BMTs) in wild-type and OCH1 knock-out strains by Mille et al. indicated that the substrate specificity differed among these enzymes. Summarizing the proposed activities, Bmt1p appeared to generate β-Mans on the outer chain, with no activity on the core glycan; Bmt2p primarily generated β-Mans on the core glycans, but did have residual activity on the outer chain; Bmt3p had no detectable activity on either core or outer chain glycans and Bmt4p was suggested to act as a capping activity to β-Mans structures on both the core and the outer chain glycans. Therefore, Bmt2p was the only enzyme that was determined to be responsible for generation of β-Mans on the core glycan and hence deletion of this gene would eliminate all β-Mans in an OCH1 knock-out strain, possessing no outer chain.
Detailed inspection of glycans generated in the och1 bmt2 double knock-out Pichia strain PBP130, reported by Mille et al. (2008) , indicated that although Bmt2p was responsible for the majority of the β-Man generating activity, α-1,2-mannosidase resistant glycoforms were still present. Subsequent analysis of the double och1 bmt2 knock-out glycoengineered strains identified a residual Man 9 GlcNAc 2 glycoform on recombinant immunoglobulin G1 (IgG1) which was resistant to α-1,2-mannosidase digestion (Gomathinayagam et al. 2011) . This glycoform, which represented less than 2% of the total glycoform pool, was purified and characterized. NMR analysis confirmed that this glycoform, represented in Figure 1 , contained the same β-Man module as observed in the outer chain isolated previously from P. pastoris (Vinogradov et al. 2000) . The common module is α-Man-(1,2)-β-Man-(1,2)-β-Man-(1,2)-α-Man-(1,2)-R, where R is either the α-1,6-Man side chain or the Man 5 GlcNAc 2 core glycan. The current investigation continues to eliminate members of the BMT family to better understand their role and to aid in the development of a P. pastoris production platform that is absent of immunogenic β-Man-associated glycans.
Results
Antibody reactivity with host cell antigen is associated with recombinant human erythropoietin glycans in a BMT2 knock-out strain Antibodies against host cell antigen (HCA) were generated in rabbits against the supernatant of the NORF (no open reading frame) strain culture. The NORF strain is genetically identical to the recombinant protein expression strain (YGLY3159) with the exception that it lacks the ORF encoding recombinant human erythropoietin (rhEPO). The HCAs were used to generate a polyclonal antibody mix, which was initially used to confirm the removal of host cell proteins from the finalized rhEPO product. However, analysis of purified rhEPO by western blot analysis [ Figure 2A , minus PNGase F (protein N-glycosidase F) lane] indicated cross-reactivity of rhEPO with the anti-HCA antibody. To assess if the cross-reactivity was associated with the peptide and/or glycan component, purified rhEPO from YGLY3159 was treated with PNGase F to remove N-linked glycans. The sodium dodecyl sulfate-polyacrylamide gel Fig. 1 . Illustration of the N-glycan containing β-Man structure. Determined by NMR by Gomathinayagam et al. (2011) .
Elimination of β-mannose in Pichia pastoris electrophoresis (SDS-PAGE) gel ( Figure 2B ) of rhEPO with or without PNGase F treatment showed a size shift of rhEPO from 37 to 22 kDa, corresponding to the removal of the three N-linked glycans. This molecular mass range is consistent with that observed by other researchers (Skibeli et al. 2001) . Western blot analysis of the same rhEPO sample (Figure 2A ) using anti-HCA antibodies showed that immunoreactivity was only observed in the untreated sample, thus suggesting that the antigen is associated with N-linked glycans on rhEPO. Analysis of the glycans indicated the presence of an α-mannosidase resistant hexose 9 -GlcNAc 2 (Hex 9 GlcNAc 2 ) glycoform. We postulated that this was a Man 9 GlcNAc 2 oligosaccharide that contained β-Man and thus initiated a strategy to eliminate the three remaining members of the BMT gene family.
Generation and confirmation of BMT1,3,4 serial knock-outs in a BMT2 knock-out strain In an attempt to elucidate the role of the BMTs in our P. pastoris strains, a series of strains were generated in which the BMT1-4 genes were deleted. Knock-out vectors were generated by cloning the 5′ and 3′ regions for each BMT gene into either URA5-, nourseothricin-(NatR) or hygromycin (HygR)-marked vectors (Figure 3 ). For the BMT1 gene knock-out, URA5-marked and NatR-marked vectors were constructed ( Figure 3A and B); for the BMT3 gene knock-out, URA5-marked and HygR-marked vectors were constructed ( Figure 3C and D) ; for the BMT4 gene knock-out, a URA5-marked vector was constructed ( Figure 3E ). The starting strain for all subsequent manipulations, YGLY3225, is a counter-selected daughter strain of YGLY3159 (bmt2Δ) which is auxotrophic for uracil. Double knock-out strains were generated by transforming YGLY3225 with the vectors listed in Table I , resulting in the strains summarized in Table II . Triple and quadruple knock-out strains were constructed using the specific vectors and starting strains listed in Table II . Although several clones from each genetic background were analyzed, only one clone from each has been exemplified in Table II to reduce complexity. As such, all data presented in this study are representative of several clones from the same genetic background. Confirmation of the BMT knockouts was done by colony polymerase chain reaction (cPCR) of each strain using the relevant primer sets listed in Table I . Figure 4 confirms the knock-out status of bmt1Δ, bmt3Δ and bmt4Δ mutants in the series of strains generated from the bmt2Δ starting strain. Lane 1 of Figure 4 showed that cPCR of the BMT2 knock-out strain (YGLY3159) using the knock-out primer set for each of BMT1, BMT3 and BMT4 produced a band for each, confirming the presence of BMT1, BMT3 and BMT4 in the BMT2 deletion strain. For each subsequent knock-out strain generated the expected pattern was confirmed, with the final lane confirming that BMT1, BMT3 and BMT4 had been eliminated from the bmt2Δ starting strain to produce a quadruple knock-out strain. The absence of BMT2 was initially confirmed in the host strain (data not shown). cPCR of each knock-out strain using the 5′ and 3′ crossover primer sets (Table I) further confirmed the knock-out profile of each strain generated (data not shown).
Deletion of additional BMT genes eliminates rhEPO immunoreactivity with anti-HCA antibody
To characterize the cross-reactivity of the series of BMT knock-out strains with an anti-HCA antibody, rhEPO was purified from the supernatants of each of the BMT knock-out strains. Purified rhEPO was then examined by enzyme-linked immunosorbent assay (ELISA), SDS-PAGE and western blot analysis ( Figure 5 ). Figure 5A is a sandwich ELISA showing the relative cross-reactivity of rhEPO to anti-HCA antibody. Purified rhEPO from the bmt2Δ strain showed relatively high reactivity with the anti-HCA antibody, consistent with the data presented in Figure 2 . rhEPO purified from the double BMT knock-outs also showed high cross-reactivity with the anti-HCA antibody, suggesting that additional BMTs may be involved in generating this reactivity. Indeed, purified rhEPO from the bmt2,1,3 and the bmt2,3,1 deletion strains did not demonstrate reactivity. However, reactivity was seen with material isolated from the bmt2,4,1 and bmt2,4,3 knock-out backgrounds albeit to a lesser extent than that observed from the bmt2 knock-out strain. These data suggest that Bmt1p and Bmt3p activities need to be eliminated in addition to the activity of Bmt2p to abolish cross-reactivity. As expected, the cross-reactivity was also eliminated in the quadruple bmt2,4,1,3 knock-out background. SDS-PAGE ( Figure 5B ) and anti-hEPO western blot ( Figure 5C ) of normalized rhEPO from supernatants isolated from this series of strains showed that rhEPO was present at similar amounts in all samples. A western blot ( Figure 5D ) using anti-HCA antibody against normalized rhEPO is consistent with the reactivity pattern observed in the sandwich ELISA. Immunoreactivity was significant with material isolated from the double bmt knock-out strains and the triple bmt2,4,1Δ strain, but to a lesser extent in the bmt2,4,3 deletion strain. However, where at least BMT1 . Vectors generated to knock-out P. pastoris BMT genes 1, 3 and 4. Represented are the three URA5-marked vectors pGLY3419 (A), pGLY3421 (C) and pGLY3411 (E), used to knock-out BMT1, BMT3 and BMT4, respectively. Also represented is the nourseothricin-marked vector pGLY3430 (B) which was used to knock-out BMT1 and the hygromycin-marked vector pGLY4472 (D), used to knock-out BMT3. Restriction enzyme sites used to linearize each vector prior to yeast transformation are underlined.
Elimination of β-mannose in Pichia pastoris
and BMT3 genes have been eliminated in a bmt2 knock-out background, cross-reactivity is primarily eliminated. For characterization purposes, the sandwich ELISA was preferred since cross-reactivity was specifically reported for rhEPO-associated antigens, due to the anti-EPO capture method used on the 96-well plate. In contrast, non-rhEPO antigens could be detected in the preparative samples analyzed by western blot using the anti-HCA polyclonal antibody mix.
Subsequent investigations in our laboratory analyzing other therapeutic recombinant glycoproteins [including the IgG1 used by Gomathinayagam et al. (2011)] have indicated that when these proteins were produced in a bmt2 knock-out strain, reactivity was observed with the anti-HCA antibody (data not shown). Conversely, when the same samples were treated with PNGase F, or when the protein was expressed in a quadruple BMT knock-out strain, reactivity was all but abolished (data not shown). This indicates that the anti-HCA antibody is specifically recognizing the β-Man glycoform and is not dependent on the recombinant protein to which it is attached.
α-Mannosidase resistant glycans are eliminated in BMT gene knock-out strains High-Man glycans that are resistant to α-mannosidase treatment have been found on the recombinant IgG1 generated from a developmental glycoengineered bmt2Δ strain (Gomathinayagam et al. 2011) . This suggested that β-Man linkages may also be present within rhEPO glycans. The percentage of α-mannosidase resistant glycans on rhEPO was measured for each of the bmt knock-out strains ( Figure 6 ). In the bmt2Δ strain, the α-mannosidase resistant glycans constituted 6% of the total glycans. However, the content of α-mannosidase resistant glycans was reduced with each subsequent bmt knock-out. For example, less than 1% of glycans from the bmt2,4,3 knock-out strain were found to be α-mannosidase resistant. However, α-mannosidase resistance was below the limit of detection on glycans from rhEPO isolated from the bmt2,1,3, bmt2,3,1 and bmt2,4,1,3 knock-out strain backgrounds. Likewise, when the same recombinant IgG1 protein used by Gomathinayagam et al. was expressed in a parallel quadruple bmt knock-out strain, no α-mannosidase resistant high-Man glycans were detected (data not shown). These results indicate that the α-mannosidase resistant glycoforms are due to the presence of β-Man linkages within these glycans and that these can be abolished by eliminating the combined activities of the BMT1, BMT2 and BMT3 gene products.
Discussion
Pichia pastoris is an important organism used for the production of therapeutic proteins. One of the main benefits of this system compared with bacterial systems lies in the fact that glycosylated proteins can be produced. However, significant differences exist in the glycosylation pathways between yeast and mammalian cells (Hamilton and Gerngross 2007) . For example, in mammals high-Man structures entering the Golgi are trimmed, whereas in yeast these structures are extended. The presence of high-Man structures on therapeutic proteins produced in yeast may be problematic. Man residues can elicit an immune response in the recipient of the therapeutic protein. In addition, Man residues can bind Man receptors on macrophages, increasing the molecule's clearance and lowering its half-life. It has been reported that the glycans on a recombinant human bile salt protein produced in a P. pastoris host contain β-linked Man residues (Trimble et al. 2004 ).
The elimination of β-linked Man in therapeutic proteins produced using a P. pastoris expression platform is essential for reducing the risk of an immunogenic response and for prolonging the in vivo half-life of engineered therapeutic proteins. Mille et al. (2008) have recently described a novel family of four BMTs (BMT1-4) in P. pastoris and demonstrated that Bmt2p is responsible for the majority of the BMT activity. During the production of therapeutic proteins, antibodies are routinely raised against HCAs derived from the production host lacking expression of the ORF of interest. Subsequently, these antibodies can be used to determine the final purity of the product. During assessment of rhEPO isolated from a developmental glycoengineered bmt2Δ strain, cross-reactivity was observed with the anti-HCA antibodies. Furthermore, this reactivity was eliminated when the glycans were removed by PNGase F treatment, suggesting that the epitope to the anti-HCA antibody resided in the N-glycan component. Analysis of the glycans indicated the presence of a low amount of a Hex 9 GlcNAc 2 α-mannosidase resistant glycoform. We postulated that this glycan contained β-Man structures and that the anti-HCA reactivity was associated with these glycoforms. Therefore, we set out to eliminate the remaining identified BMT genes as a means to prevent crossreactivity to anti-HCA antibodies. A series of BMT1, BMT3 and BMT4 gene knock-out vectors was constructed and transformed into a bmt2Δ strain. The resulting strains had a combination of double, triple or quadruple BMT gene knock-outs. Analysis of these BMT gene knock-out strains showed a reduction in reactivity with the anti-HCA antibody that was dependent on the combination of BMT gene knock-outs. The Table I were used to confirm the knock-out of internal fragments of the BMT gene ORFs. Fig. 5 . Characterization of rhEPO produced in various BMT gene knock-out backgrounds. ELISA analysis (A) using anti-HCA antibody to quantitate the relative cross-reactivity observed on recombinant glycoprotein purified from the supernatants of various BMT gene knock-out strains. Coomassie stained SDS-PAGE (B) and anti-EPO western blot (C) analyses of normalized rhEPO isolated from various BMT gene knock-out strains. Western blot analysis of normalized rhEPO using anti-HCA antibody for detection (D). Elimination of β-mannose in Pichia pastoris various double knock-outs (bmt2,1Δ, bmt2,3Δ and bmt2,4Δ) showed little, if any, reduction in reactivity compared with the material from the bmt2Δ parent strain. The rhEPO from triple knock-outs of bmt2,4,3Δ and bmt2,4,1Δ also showed a slight to moderate reduction in reactivity with the anti-HCA antibody. In contrast, the material isolated from the triple bmt2,1,3 and bmt2,3,1 knock-outs, and the quadruple bmt2,4,1,3 knock-out demonstrated no significant remaining cross-reactivity. As such, this suggests that at least the elimination of the BMT1, BMT2 and BMT3 genes are required to completely abolish the reactive epitope on the P. pastoris glycans. Furthermore, it was observed that the order in which these three BMT genes were knocked-out is not an important consideration since the rhEPO from the bmt2,1,3Δ and bmt2,3,1Δ strains had similar reactivity. Likewise, rhEPO glycans isolated from these knock-out backgrounds no longer demonstrated the presence of α-mannosidase resistant high-Man glycoforms.
In a parallel study in our laboratory, Gomathinayagam et al. (2011) isolated an α-mannosidase resistant Man 9 GlcNAc 2 glycoform from recombinant IgG1 expressed in an och1 bmt2 double knock-out strain. NMR analysis of this glycoform confirmed that β-Man was present in the core N-glycan. Previously, Mille et al. (2008) suggested that Bmt2p may be an initiator of β-Man transfer to the core glycan, so by eliminating it the remaining BMTs would not be able to extend the Man chain. However, in the BMT2 deletion strain, they did not go on to characterize the low levels of residual α-mannosidase resistant glycans present in their samples following the elimination of BMT2 in the och1 knock-out background. From the present study, it is suspected that these low levels of glycoforms in the previous study were β-Man containing glycans. As such the elimination of Bmt2p activity alone is not sufficient to remove all traces of β-Man in an och1 knock-out background. It is also plausible, under certain conditions, in the absence of Bmt2p activity, that the expression of Bmt1p and Bmt3p can be up-regulated and confer β-Man transfer to core N-glycans.
The data presented in this study are in agreement with that presented by Mille et al. with regard to BMT4 activity. Due to the lower homology of BMT4 with the other BMTs, it was postulated to have an α-1,2-Man capping activity and thus would add the final Man to the core or outer chain β-Man structures. As such, in a bmt1,2,3 gene knock-out background, Bmt4p would not be expected to produce β-Man-associated structures, as observed here. In summary, we have demonstrated the elimination of Man-associated α-mannosidase resistant glycans produced in P. pastoris thus providing for even further control over glycosylation and glycoprotein homogeneity.
Materials and methods
Reagents and strains Escherichia coli strains TOP10 or XL10-Gold were used for recombinant DNA work. PNGase F, DNA restriction and DNA modification enzymes were obtained from New England BioLabs (Ipswich, MA) and used as directed by the manufacturer. α-Mannosidase was obtained from Glyko (San Rafael, CA). Oligonucleotides were obtained from Integrated DNA (Nett et al., in preparation) (och1Δ, pno1Δ, mnn4BΔ, bmt2Δ, his1Δ, Kluyveromyces lactis and Mus musculus UDP-GlcNAc transporters, M. musculus α-1,2-MnsI, Homo sapiens β-1,2-GlcNAc transferase I, Rattus norvegicus β-1,2-GlcNAc transferase II, Drosophila melanogaster MnsII, Schizosaccharomyces pombe Gal epimerase, D. melanogaster UDP-Gal transporter, H. sapiens β-1,4-galactosyl transferase, H. sapiens UDPGlcNAc-2-epimerase/N-acetylmannosamine kinase, H. sapiens N-acetyl-neuraminate-9-phosphate synthase, H. sapiens cytodine monophosphate (CMP)-Sia synthase, M. musculus CMP-Sia transporter and M. musculus α-2,6-sialyl transferase) expressing sialylated glycans (Hamilton et al. 2006 ) was used as the starting strain for material generation and genetic manipulations.
Recombinant protein expression
The growth of strains was performed in bioreactors using inoculum seed flasks as described as follows. The inoculum seed flasks were inoculated from yeast patches (isolated from a single colony) on agar plates into 0.1 L of 4% BSGY in a 0.5 L baffled flask. Seed flasks were grown at 180 rpm and 24°C (Innova 44, New Brunswick Scientific, NJ) for 48 h. Cultivations were done in 1 L (fedbatch-pro, DASGIP BioTools, MA) bioreactors. Vessels were charged with 0.54 L of 0.22 μm filtered 4% BSGY media (with 4 drops/L Sigma 204 antifoam) and autoclaved at 121°C for 60 min. After sterilization and cooling, the aeration, agitation and temperatures were set to 0.7 vvm, 400 rpm and 24°C, respectively. The pH was adjusted to and controlled at 6.5 using 30% ammonium hydroxide. Inoculation of a prepared bioreactor occurred aseptically with 60 mL from a seed flask. Agitation was ramped to maintain 20% dissolved oxygen (DO) saturation. After the initial glycerol charge was consumed, denoted by a sharp increase in the DO, a 50% w/w glycerol solution containing 5 mg/L biotin and 32.3 mg/L PMTi4 was triggered to feed at 3.68 mL/h for 8 h. During the glycerol fed-batch phase, 0.375 mL of PTM2 salts was injected manually. Completion of the glycerol fed-batch was followed by a 0.5 h starvation period and initiation of the induction phase. A continuous feed of a 50% v/v methanol solution containing 2.5 mg/L biotin and 6.25 mL/L PTM2 salts was started at a flat rate of 2.16 mL/h. Injections of 0.5 mL of protease inhibitor solution containing 3.6 mg/mL pepstatin A and 2.2 mg/mL chymostatin (in methanol) were added at the start of induction and after each 24 h of induction time. Additionally, injections of 0.25 mL of 1.9 mg/mL PMTi4 (in methanol) were added each 24 h of induction. Individual fermentations were harvested D Hopkins et al. within 36-66 h of induction. The culture broth was clarified by centrifugation (Sorvall Evolution RC, Thermo Scientific, NC) at 15810 × g for 40 min and the resulting supernatant was submitted for purification.
Purification of rhEPO
A two-step purification protocol, employing Blue sepharose™ 6 fast flow ( pseudo-ligand affinity chromatography) followed by CHT ® Ceramic Hydroxyapatite (mix-mode ion exchange chromatography), was employed to purify the rhEPO protein. First, the cell-free culture supernatant was filtered using a 0.22 μm filter and the clarified culture supernatant was allowed to bind to Blue sepharose™ 6 fast flow resin (GE Healthcare, PA, Cat# 17-0948-01) pre-equilibrated in equilibration buffer (50 mmol/L 3-(N-morpholino)propanesulfonic acid (MOPS) buffer, pH 7.0). After sample loading, the column was washed with 3 column volumes (CVs) of equilibration buffer containing 200 mmol/L sodium chloride to remove unbound host cell proteins. The bound rhEPO protein was eluted by a single step elution using a 1 M sodium chloride elution buffer (50 mmol/L MOPS buffer, pH 7.0, 1 M sodium chloride). The eluted fraction was adjusted to 10 mmol/L calcium chloride concentration and subsequently applied to column containing CHT ® Ceramic Hydroxyapatite type I 40 μm resin (Bio-Rad Laboratories, Hercules, CA, Cat #157-0040) that was pre-equilibrated with the equilibration buffer (50 mmol/L MOPS, 1 M sodium chloride, 10 mmol/L calcium chloride, pH 7.0). After loading, the column wash was executed with 3 CVs of equilibration buffer and the rhEPO protein was eluted by elution buffer (62.5 mmol/L sodium phosphate, pH 7.0). The eluted fractions containing rhEPO protein was sterile filtered using 0.22 μm polyethersulfone (PES) membrane filter and stored at −20°C until further analysis. The concentration of the protein was measured by Bio-Rad Protein Assay and its purity was analyzed by 4-20% SDS-PAGE.
Host cell antibody generation HCA antibody was prepared in rabbits (Rockland Immunochemicals Inc., Gilbertsville, PA) using the supernatant from NORF strain cultures. The NORF strain is genetically the same as YGLY3159 except that it lacks the ORF encoding the mature hEPO. NORF strain fermentation supernatant prepared in complete Freund's adjuvant was injected into rabbits, which were then boosted three times with fermentation supernatant prepared in Incomplete Freund's adjuvant. After 45 days, the rabbits were bled and polyclonal antibodies to HCA were prepared using the standard methods, e.g. rabbit polyclonal IgG 9161 F072208-S was SLr protein A purified.
SDS-PAGE and western blot analysis of rhEPO produced in various BMT gene knock-out strains Western blots for detecting P. pastoris HCA were performed as follows. Purified rhEPO-containing samples were reduced in sample loading buffer, of which 1 μg (normalized for rhEPO protein) was then applied to the wells of 4-20% polyacrylamide SDS Tris-HCl (4-20% SDS-PAGE) gels (Bio-Rad Laboratories) and electrophoresed at 150 V for 60 min. The resolved proteins were electro-transferred to nitrocellulose membranes at 100 V for 60 min. After transfer, the membranes were blocked for 1 h with 1% Blocking Solution (Roche Diagnostics, Township of Branchburg, NJ). After blocking, the membranes were probed with the rabbit anti-HCA polyclonal antibody ( primary antibody) diluted 1:3000. The membranes were washed and goat anti-rabbit IgG (H + L) (Cat. #31460 from Pierce, Rockford, IL) conjugated to horseradish peroxidase (HRP) was added at a 1:5000 dilution. The membranes were washed prior to detection using 3,3′-diaminobenzidine. For detecting rhEPO protein, the primary antibody EPO (B-4) HRP-conjugated antibody was used at a 1:1000 dilution (Cat. #SC5290 from Santa Cruz Biotechnology, Santa Cruz, CA). A secondary antibody was not used. Routinely, the rhEPO samples were electrophoresed in parallel with rhEPO samples that had been deglycosylated with PNGase F treatment. Deglycosylation was performed in 50 µL samples to which 1 μL of PNGase F enzyme at 500 units/µL had been added. After incubation at 37°C for 2 h, the samples were reduced in sample loading buffer and 1 μL of aliquots was removed and applied to the SDS gels as described in the previous paragraph.
For rhEPO protein normalization, purified rhEPO-containing samples from various BMT gene knock-out strains were electrophoresed on SDS-PAGE gel and based on in gel quantification of rhEPO protein, the volume of rhEPO-containing samples was adjusted to load 1 µg/well for the anti-HCA antibody western blot.
Generation of knock-out vectors
Generation of BMT1 knock-out vectors. DNA fragments corresponding to 5′-and 3′-flanking regions of the BMT1 ORF were amplified using PfuUltra™ DNA polymerase (Stratagene, La Jolla, CA) and genomic DNA from the P. pastoris strain NRRL-Y11430 as template. The primer pairs SH550 + SH551 (see Table III for all primer sequences) and SH552 + SH553 were used to amplify 423 and 699 bp fragments for BMT1 5′ and 3′, respectively. Following incubation with ExTaq™ (TaKaRa, Bio. Inc., Japan) for 10 min at 72°C, the amplified fragments were cloned into pCR2.1 (Invitrogen, Carlsbad, CA) and transformed into TOP10 competent cells. DNA sequencing confirmed the BMT1 5′-and 3′-flanking regions were correct and the resultant vectors designated pGLY3405 and pGLY3406, respectively.
A 423 bp BMT1 5′-flanking region fragment was digested from pGLY3405 using SphI and subcloned into a P. pastoris URA5-blaster vector similar to pJN396 , previously digested with the same restriction enzyme and treated with calf intestinal alkaline phosphatase (CIAP). Following transformation into XL10 Gold competent cells, the resultant vector was designated pGLY3413. The vector pGLY3406 was digested with EcoRI to release a 691 bp fragment encoding the BMT1 3′-flanking region and subcloned into pGLY3413 previously digested with the same enzyme and CIAP-treated. The ligation product was transformed into XL10 Gold competent cells and designated pGLY3419. This final BMT1::URA5 knock-out vector is illustrated in Figure 3A .
Elimination of β-mannose in Pichia pastoris A similar strategy was used to generate a dominant-marked BMT1 knock-out vector. Briefly, the vector pGLY568, a vector derived from pUC19 containing the Nourseothricin (Nat) marker cassette from pAG25 (Goldstein and McCusker 1999 ) and a glyceraldehyde 3-phosphate dehydrogenase (GAPDH) promoter/cytochrome C (CYC) terminator expression cassette, was digested with BamHI and BglII, blunted and CIAP-treated to produce 3.9 kb fragment. The BMT1 5′-flanking region was digested from pGLY3405 with SphI, blunted and the 412 bp fragment isolated was subcloned into the pGLY568 fragment. This resultant vector was designated pGLY3424. The BMT1 3′-flanking region was subcloned into this vector from pGLY3406 using EcoRI as described for the cloning of this fragment into pGLY3413 above. The resultant BMT1::Nat knock-out vector was designated pGLY3430 and is illustrated in Figure 3B .
Generation of BMT3 knock-out vectors. The BMT3 5′-and 3′-flanking regions were amplified from Pichia genomic DNA as described in the Generation of BMT1 knock-out vectors section above using the primer sets SH544 + SH545 and SH554 + SH555, to generate 562 and 392 bp fragments, respectively. Following cloning into pCR2.1 and sequencing the vectors were designated pGLY3397 and pGLY3402, encoding the BMT3 5′ and 3′ regions, respectively.
The 551 bp BMT3 5′ region was extracted from pGLY3397 using EcoRI and subcloned into the Pichia URA5-blaster vector previously digested with the same enzyme and CIAP-treated. The resulting vector was designated pGLY3412. The vector pGLY3402 was digested with SphI to generate a 382 bp fragment encoding the BMT3 3′ region, which was subcloned into pGLY3412 digested with the same enzyme and CIAP-treated. The resultant vector was designated pGLY3421 and is illustrated in Figure 3C .
A dominant-marked BMT3 knock-out vector was also generated. Briefly, the vector pGLY568 was digested with EcoRI and CIAP-treated to produce 4.7 kb fragment. The BMT3 5′-flanking region was digested from pGLY3397 with EcoRI and subcloned into the pGLY568 fragment. This resultant vector was designated pGLY3425. A fragment corresponding to the 1.7 kb BglII/ SacI fragment from pAG32 (Goldstein and McCusker 1999) , encoding the hygromycin resistance marker, was subcloned into pGLY3425, previously digested with the same enzymes, to replace the nourseothricin marker. The resultant vector was designated pGLY4466. Subsequently, the BMT3 3′-flanking region was subcloned into pGLY4466 using SphI as described in the previous paragraph for the generation of pGLY3421. The resultant BMT3::Hyg knock-out vector was designated pGLY4472 and is illustrated in Figure 3D .
Generation of BMT4::URA5 vector. The BMT4 5′-and 3′-flanking regions were amplified from Pichia genomic DNA as described in the Generation of BMT1 knock-out vectors section above using the primer sets SH538 + SH539 and SH542 + SH543, to generate 1051 and 708 bp fragments, respectively. Following cloning into pCR2.1 and sequencing, the vectors were designated pGLY3400 and pGLY3398, encoding the BMT4 5′ and 3′ regions, respectively.
The BMT4 knock-out vector was generated by subcloning the 1046 bp HindIII/SphI fragment encoding the BMT4 5′ region into the URA5-blaster to generate pGLY3424. Subsequently, the 700 bp EcoRI fragment encoding the BMT4 3′ region was subcloned into pGLY3424 to generate the BMT4 knock-out vector pGLY3411, as illustrated in Figure 3E .
Generation of BMT gene knock-out strains
The P. pastoris glycoengineered cell line YGLY3159 (Nett et al., in preparation) was counter-selected on 5-fluoroorotic acid to generate the uracil auxotrophic strain YGLY3225, which was used as the starting strain for all manipulations. Double BMT gene knock-out strains were obtained by transforming this host strain, containing the bmt2 gene knockout, with pGLY3411, pGLY3419 or pGLY3421 digested with the restriction enzymes summarized in Table I , to delete BMT4, BMT1 or BMT3, respectively. The transformants were plated on uracil minus plates to select for incorporation of the transformed vectors. Subsequently, successful knock-out of each BMT gene was confirmed by PCR using the 5′, 3′ and knockout primer sets listed in Table I . The resultant double BMT gene knock-out strains are described in Table II . Subsequently, using a similar strategy, a third BMT gene was knocked-out to generate the triple knock-out strains described in Table II . For selection of dominant markers, transformants were plated on YSD containing 100 μg/mL of either nourseothricin or hygromycin. Finally, the quadruple BMT gene knock-out strain was generated by transforming the triple knock-out strain YGLY6660 with pGLY4472. The successful knock-out of each sequential BMT gene was confirmed in all strains by PCR using the 5′, 3′ and knock-out primer sets listed in Table I . Although multiple strains from each genetic background were assessed, with each giving similar results, a list of a representative strain from each knock-out background is described in Table II to reduce complexity.
ELISA characterization of rhEPO produced in various BMT gene knock-out strains Sandwich ELISAs for detecting rhEPO were performed as follows. The wells of 96-well ELISA plates were coated with 1 μg/well of mouse anti-hEPO monoclonal antibody diluted in Tris ELISA Diluent/ Blocking Solution (TEDBS; Virolabs, Chantilly, VA). After 60 min, the wells were washed three times with Tris ELISA Wash Buffer (TEWB; Virolabs). The wells were then blocked for 60 min with Tris-buffered saline. One hundred microliters of purified rhEPO-containing samples, diluted 1:200 in TEDBS then sequentially 2-fold down a column, was added to the wells. The standard for the ELISA was rhEPO purified from YGLY3159. Primary detection used the rabbit anti-hEPO polyclonal antibody at a 1:1000 dilution in TEDBS. After 60 min, the wells were washed with TEWB three times. The rabbit anti-hEPO antibody was detected using goat anti-rabbit antibody conjugated to alkaline phosphatase at a 1:10,000 dilution in TEDBS. After 60 min, the wells were washed three times with TEWB and bound secondary antibody detected using 4-methylumbelliferyl phosphate. Plates were incubated for 60 min. The ELISA plates were read usng a Tecan Genios Multidetection Microplate Reader at 340 nm excitation wavelength and 465 nm emission wavelengths. Sandwich ELISAs for detecting P. pastoris HCA were performed as described in the previous paragraph for rhEPO except for the following changes. Instead of adding serial dilutions of rhEPO, this protein was normalized across the plate at 800 ng/mL based on the ELISA quantitation described in the previous paragraph. Subsequently, crossreactivity with the rabbit anti-HCA polyclonal antibody was assessed, starting with a 1:200 dilution in TEDBS and serially diluting 2-fold in TEDBS down a column ending with the seventh well at a 1:12,800 dilution. The final well in each column served as a negative control. The standard for the ELISA was rhEPO purified from YGLY3159. Subsequent processing of bound anti-HCA antibody was as described in the previous paragraph for anti-hEPO antibody.
Glycan characterization
PNGase F, 2-aminobenzamide labeling and high-performance liquid chromatography (HPLC) analysis of glycans has been described previously (Hamilton et al. 2006) . α-Mannosidase treatment was performed by adding 0.2 μL of enzyme to dried sample resuspended in 50 μL of ammonium acetate, pH 5.0, and incubation overnight at 37°C, with subsequent analysis by HPLC. To quantitate the percentage of α-mannosidase resistant glycans present, the ratio of α-mannosidase resistant high-Man glycans was compared with the total glycan pool. This was achieved by adding the HPLC peak areas of the α-mannosidase resistant high-Man structures, i.e. those high-Man glycans larger than Man 5 GlcNAc 2 , and comparing them to the total peak area of the remaining glycan pool. The presence of high-Man structures larger than Man 5 GlcNAc 2, which were not digested by the α-mannosidase, was confirmed by Gomathinayagam et al. (2011) to possess β-Man structures.
